|
1
|
Church T: Exercise in obesity, metabolic
syndrome, and diabetes. Prog Cardiovasc Dis. 53:412–418. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Abete I, Goyenechea E, Zulet MA and
Martinez JA: Obesity and metabolic syndrome: potential benefit from
specific nutritional components. Nutr Metab Cardiovasc Dis.
21(Suppl 2): B1–B15. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Azimi-Nezhad M, Herbeth B, Siest G, et al:
High prevalence of metabolic syndrome in Iran in comparison with
France: what are the components that explain this? Metab Syndr
Relat Disord. 10:181–188. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Waite KA and Eng C: Protean PTEN:
form and function. Am J Hum Genet. 70:829–844. 2002.PubMed/NCBI
|
|
5
|
Weng L, Brown J and Eng C: PTEN
induces apoptosis and cell cycle arrest through
phosphoinositol-3-kinase/Akt-dependent and -independent pathways.
Hum Mol Genet. 10:237–242. 2001. View Article : Google Scholar
|
|
6
|
Fernández S, García-García M and
Torres-Alemán I: Modulation by insulin-like growth factor I of the
phosphatase PTEN in astrocytes. Biochim Biophys Acta.
1783:803–812. 2008.PubMed/NCBI
|
|
7
|
Maehama T and Dixon JE: The tumor
suppressor, PTEN/MMAC1, dephosphorylates the lipid second
messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem.
273:13375–13378. 1998.
|
|
8
|
Leslie NR and Downes CP: PTEN: The
down side of PI 3-kinase signalling. Cell Signal. 14:285–295. 2002.
View Article : Google Scholar
|
|
9
|
Wijesekara N, Konrad D, Eweida M, et al:
Muscle-specific PTEN deletion protects against insulin
resistance and diabetes. Mol Cell Biol. 25:1135–1145. 2005.
|
|
10
|
Clément S, Krause U, Desmedt F, et al: The
lipid phosphatase SHIP2 controls insulin sensitivity. Nature.
409:92–97. 2001.
|
|
11
|
Qu Y, Sun L, Yang Z and Han R: Variation
in the PTEN-induced putative kinase 1 gene associated with
the increase risk of type 2 diabetes in northern Chinese. J Genet.
90:125–128. 2011.
|
|
12
|
Tsugawa K, Jones MK, Akahoshi T, et al:
Abnormal PTEN expression in portal hypertensive gastric
mucosa: a key to impaired PI 3-kinase/Akt activation and delayed
injury healing? FASEB J. 17:2316–2318. 2003.PubMed/NCBI
|
|
13
|
Hers I, Vincent EE and Tavaré JM: Akt
signalling in health and disease. Cell Signal. 23:1515–1527. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mocanu MM and Yellon DM: PTEN, the
Achilles’ heel of myocardial ischaemia/reperfusion injury? Br J
Pharmacol. 150:833–838. 2007. View Article : Google Scholar
|
|
15
|
Butler M, McKay RA, Popoff IJ, et al:
Specific inhibition of PTEN expression reverses
hyperglycemia in diabetic mice. Diabetes. 51:1028–1034. 2002.
|
|
16
|
Besson A, Robbins SM and Yong VW:
PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis.
Eur J Biochem. 263:605–611. 1999. View Article : Google Scholar
|
|
17
|
Keniry M and Parsons R: The role of
PTEN signaling perturbations in cancer and in targeted
therapy. Oncogene. 27:5477–5485. 2008.
|
|
18
|
Mirmohammadsadegh A, Marini A, Nambiar S,
et al: Epigenetic silencing of the PTEN gene in melanoma.
Cancer Res. 66:6546–6552. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Expert Panel on Detection, Evaluation, and
Treatment of High Blood Cholesterol in Adults. Executive Summary of
the Third Report of The National Cholesterol Education Program
(NCEP) Expert Panel on Detection, Evaluation, and Treatment of High
Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA.
285:2486–2497. 2001. View Article : Google Scholar
|
|
20
|
Kaykhaei MA, Hashemi M, Narouie B, et al:
Prevalence of metabolic syndrome in adult population from Zahedan,
southeast Iran. Iran J Public Health. 41:70–76. 2012.PubMed/NCBI
|
|
21
|
Hashemi M, Kordi-Tamandani DM, Sharifi N,
et al: Serum paraoxonase and arylesterase activities in metabolic
syndrome in Zahedan, southeast Iran. Eur J Endocrinol. 164:219–222.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kordi-Tamandani DM, Hashemi M, Sharifi N,
Kaykhaei MA and Torkamanzehi A: Association between paraoxonase-1
gene polymorphisms and risk of metabolic syndrome. Mol Biol Rep.
39:937–943. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hashemi M, Moazeni-Roodi AK, Fazaeli A, et
al: Lack of association between paraoxonase-1 Q192R polymorphism
and rheumatoid arthritis in southeast Iran. Genet Mol Res.
9:333–339. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tiwari SK, Manoj G, Prasanth K, et al:
Simplified and versatile method for bisulfite-based DNA methylation
analysis of small amounts of DNA. J Clin Lab Anal. 23:172–174.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Goel A, Arnold CN, Niedzwiecki D, et al:
Frequent inactivation of PTEN by promoter hypermethylation
in microsatellite instability-high sporadic colorectal cancers.
Cancer Res. 64:3014–3021. 2004.
|
|
26
|
Mottillo S, Filion KB, Genest J, et al:
The metabolic syndrome and cardiovascular risk a systematic review
and meta-analysis. J Am Coll Cardiol. 56:1113–1132. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cameron AJ, Shaw JE and Zimmet PZ: The
metabolic syndrome: prevalence in worldwide populations. Endocrinol
Metab Clin North Am. 33:351–375. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Peyrou M, Bourgoin L and Foti M:
PTEN in non-alcoholic fatty liver disease/non-alcoholic
steatohepatitis and cancer. Dig Dis. 28:236–246. 2010. View Article : Google Scholar
|
|
29
|
Vinciguerra M and Foti M: PTEN at
the crossroad of metabolic diseases and cancer in the liver. Ann
Hepatol. 7:192–199. 2008.
|
|
30
|
Ding J, Gao Y, Liu R, Xu F and Liu H:
Association of PTEN polymorphisms with susceptibility to
hepatocellular carcinoma in a Han Chinese population. DNA Cell
Biol. 30:229–234. 2011.
|
|
31
|
Zhou XP, Hampel H, Roggenbuck J, Saba N,
Prior TW and Eng C: A 39-bp deletion polymorphism in PTEN in
African American individuals: implications for molecular diagnostic
testing. J Mol Diagn. 4:114–117. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sadeq V, Isar N and Manoochehr T:
Association of sporadic breast cancer with PTEN/MMAC1/TEP1
promoter hypermethylation. Med Oncol. 28:420–423. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Phuong NT, Kim SK, Lim SC, et al: Role of
PTEN promoter methylation in tamoxifen-resistant breast
cancer cells. Breast Cancer Res Treat. 130:73–83. 2011.
|
|
34
|
Rizvi MM, Alam MS, Ali A, Mehdi SJ, Batra
S and Mandal AK: Aberrant promoter methylation and inactivation of
PTEN gene in cervical carcinoma from Indian population. J
Cancer Res Clin Oncol. 137:1255–1262. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hou P, Ji M and Xing M: Association of
PTEN gene methylation with genetic alterations in the
phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid
tumors. Cancer. 113:2440–2447. 2008.PubMed/NCBI
|
|
36
|
Rutledge AC and Adeli K: Fructose and the
metabolic syndrome: pathophysiology and molecular mechanisms. Nutr
Rev. 65:S13–S23. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ravi Y, Selvendiran K, Meduru S, et al:
Dysregulation of PTEN in cardiopulmonary vascular remodeling
induced by pulmonary hypertension. Cell Biochem Biophys. Dec
29–2011.(Epub ahead of print).
|
